5 Tax Bill Conference Report Sections for Agents to Watch
9 Details That Could Be Signs of Life Insurance Fraud
Americo Introduces a Single-Premium Immediate LTCI Policy
A long-running lawsuit between the Trump administration, House Republicans and Democratic attorneys general over billions of dollars of Affordable Care Act public exchange plan subsidies has been settled, according to an agreement filed in federal court Friday.
The settlement agreement, details of which weren’t available in the filings but described as “conditional,” could pave the way for eventual payment of the cost-sharing reduction payments, or CSRs. The CSRs had been paid to health insurers as a way to subsidize some lower-income patients’ insurance co-payments and deductibles, allowing them easier access to health care.
(Related: ACA Mandate Clobbers ACA Subsidy: CBO)
The Trump administration had stopped making the payments, throwing the Affordable Care Act’s markets into chaos and causing premiums to rise, and state Democratic attorneys general continued the legal effort to try and preserve the subsidies.
candlestick chart: Investment Technology Group, Inc.(ITG)
- [By Jon C. Ogg]
Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by KeefeBruyette & Woods.
Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.
candlestick chart: Nu Skin Enterprises Inc.(NUS)
- [By Ben Levisohn]
Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:
“Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…
Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.
Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.
Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.
- [By Roberto Pedone]
Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.
Monday’s Volume: 2 million
Three-Month Average Volume: 900,802
Volume % Change: 85%
From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.
Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.
- [By Scott Rubin]
Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.
- [By Craig Jones]
Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.
candlestick chart: Vanguard Extended Duration Treasury ETF (EDV)
- [By Todd Shriber, ETF Professor]
The 11 ETF fee cuts unveiled by Vanguard include a significant portion of the issuer's fixed income lineup. All of the following saw annual fees reduced to 0.07 percent from 0.1 percent:
Vanguard Extended Duration Treasury ETF (NYSE: EDV). Vanguard Intermediate-Term Bond ETF (NYSE: BIV). Vanguard Intmdte Tm Govt Bd ETF (NASDAQ: VGIT). Vanguard Long Term Corporate Bond ETF (NASDAQ: VCLT). Vanguard Lg Term Govt Bd ETF (NASDAQ: VGLT). Vanguard Mortgage Bkd Sects ETF (NASDAQ: VMBS).
and the Vanguard Short Term Corporate Bond ETF (NASDAQ: VCSH).
candlestick chart: VALE S.A.(VALE)
- [By Craig Jones]
On CNBC's Fast Money Halftime Report, Jon Najarian spoke about unusually high put options activity in Arconic Inc (NYSE: ARNC) and Vale SA (ADR) (NYSE: VALE).
- [By Ben Levisohn]
Mosaic (MOS) tumbled to the bottom of the S&P 500 today after announcing that it would buy Vale’s (VALE) fertilizer unit.
Mosaicdropped 1.1% to $27.77 today, while the S&P 500 advanced 0.2% to 2,262.53.
candlestick chart: Intercontinental Exchange Inc.(ICE)
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .
Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .
candlestick chart: Vanda Pharmaceuticals Inc.(VNDA)
- [By Roberto Pedone]
Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.
If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.
Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.
Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.